This page lists all pharmaceutical reports related to the field of Psychiatric, Addictive & Sleep Disorders. The reports include market research reports and pipeline analyses.
Displaying 101 - 113 of 113 results
- Risperdal Consta (Schizophrenia) – Analysis and Forecasts to 2020
- Seroquel (Schizophrenia) – Analysis and Forecasts to 2020
- Zyprexa (Schizophrenia) – Analysis and Forecasts to 2018
- Abilify (Schizophrenia) – Analysis and Forecasts to 2020
- Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
- GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
- RG1678 (Schizophrenia) – Analysis and Forecasts to 2020
- Cariprazine (Schizophrenia) – Analysis and Forecasts to 2020
- Invega Sustenna (Schizophrenia) – Analysis and Forecasts to 2020
- Seroquel XR (Schizophrenia) – Analysis and Forecasts to 2020
- Restless Leg Syndrome (RLS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018